Eiji Nanba

Eiji Nanba

Auto-generated profile, based on publicly available information

Eiji Nanba

Gene Research Center, Tottori University, Yonago, Japan

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 July 2002 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
YSYuko Saito
Yuko Saito
KSKinuko Suzuki
Kinuko Suzuki
ENEiji Nanba
Eiji Nanba
TYToshiyuki Yamamoto
Toshiyuki Yamamoto
KOKousaku Ohno
Kousaku Ohno
SMShigeo Murayama
Shigeo Murayama

28 June 2004 in American Journal of Medical Genetics Part B: Neuropsychiatric Genetics
Verified
Journal Article
Closed access
PDF file
TMTetsuya Marui
Tetsuya Marui
OHOhiko Hashimoto
Ohiko Hashimoto
ENEiji Nanba
Eiji Nanba
CKChieko Kato
Chieko Kato
MTMamoru Tochigi
Mamoru Tochigi
TSTsukasa Sasaki
Tsukasa Sasaki

4 November 2014 in MedChemComm
Verified
Journal Article
Closed access
PDF file
SKShinichi Kuno
Shinichi Kuno
KHKatsumi Higaki
Katsumi Higaki
ATAtsushi Takahashi
Atsushi Takahashi
ENEiji Nanba
Eiji Nanba
SOSeiichiro Ogawa
Seiichiro Ogawa
The development of second-generation valienamine-type chemical chaperones for GM1-gangliosidosis is described. Several N-substituted (+)-conduramine F-4 derivatives were designed as novel chemical chaperones based on a lead chaperone compound, N-octyl-4-epi-β-valienamine, to decrease the inhibitory activity while increasing the enzyme enhancement activity. Among the derivatives synthesized during this study, a conduramine derivative with an N-cyclohexylmethyl group has demonstrated significant enhancement of R201C mutated β-galactosidase activity.

1 September 2007 in Brain and Development
Verified
Journal Article
Open access
PDF file
NINoriko Itaba-Matsumoto
Noriko Itaba-Matsumoto
SMShinji Maegawa
Shinji Maegawa
HYHidehisa Yamagata
Hidehisa Yamagata
IKIkuko Kondo
Ikuko Kondo
MOMitsuo Oshimura
Mitsuo Oshimura
ENEiji Nanba
Eiji Nanba
Rett syndrome (RTT) is an X-linked severe neurodevelopmental disorder mostly affecting female and is mainly caused by mutations of methyl-CpG-binding protein 2 gene (MECP2). MECP2, which has a crucial role for transcriptional repression and chromatin remodeling, consists of methyl-CpG binding domain (MBD) and transcriptional repression domain (TRD). Paternally imprinted distal-less homeobox gene 5 (DLX5), that has an important role for the development of gamma-aminobutyric acid (GABA)-ergic neurons, was identified as a target of MECP2 recently. We selected the 12 samples from the 40 RTT lymphoblast cell lines by a mononucleotide repeat polymorphism within the 3'UTR of DLX5. In 12 samples, 5 and 6 samples have the mutations located in MBD and TRD, respectively. No expression and 25-75% expression of the mutated MECP2 allele were detected in 4 samples with MBD mutation and 4 samples with TRD mutation. In this study, the expression of mutated MECP2 alleles was low especially in the samples with the MBD mutation suggesting the biased frequency of the cells during the culture. However, a sample with high expression of mutated MECP2 in TRD mutation showed bialleic expression of DLX5 suggesting loss of imprinting.

1 October 2015
Verified
Journal Article
Closed access
KHKatsumi Higaki
Katsumi Higaki
ENEiji Nanba
Eiji Nanba

26 September 2000 in Human Mutation
Verified
Journal Article
Closed access
PDF file
JPJudy R. Pipo
Judy R. Pipo
TYToshiyuki Yamamoto
Toshiyuki Yamamoto
HTHiromasa Takeda
Hiromasa Takeda
SMShinji Maegawa
Shinji Maegawa
ENEiji Nanba
Eiji Nanba
KTKenzo Takeshita
Kenzo Takeshita